Federal Gov't Won't March In When It Comes To Drug Prices

Law360, New York (July 11, 2016, 4:36 PM EDT) -- John M. Clerici

Phillip Bradley Over 50 members of Congress, led by Rep. Lloyd Doggett, D-Texas, sent a letter to Department of Health and Human Services Secretary Sylvia Matthews Burwell and to National Institutes of Health Director Francis Collins on Jan. 11, 2016, urging the agencies “to utilize your existing statutory authority to respond to the soaring cost of pharmaceuticals” to address “price gouging” by pharmaceutical manufacturers. In particular, the members of Congress requested that the NIH reverse its long-standing interpretation of the Bayh-Dole Act of 1980 and to exercise statutory “march-in” rights to effectuate price controls on patented drugs developed in whole...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!